TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文
About Us About Us

COMPANY PROFILE

Transcenta is a clinical stage global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. Transcenta has established global footprint, with Headquarter and Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and Business Development in Boston and Los Angeles, US. Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Upon the latest financing, the company has raised over $342 million from globally prominent investors.

Our Team

Leadership Leadership
Directors Directors
Advisors Advisors

MILESTONES

Oct 2012
Mabspace established
Jun 2013
Immune Tolerance Breaking Technology Platform developed
Mar 2015
Partnership with Hengrui & GenorBio
Oct 2015
Mabspace completed series A US$ 15M
Aug 2016
HJB established and completed series A US$ 10M
Mar 2017
Partnership with G-CON to build T-BLOC facility in Hangzhou
Aug 2017
HJB completed series B US$ 37M
Feb 2018
FDA Clearance of
MSB2311 IND
Apr 2018
MSB2311 initiated Phase I clinical trial in US
May 2018
Mabspace completed series B US$ 40M
Jun 2018
HJB completed series B+ US$ 35M;
NMPA Clearance of MSB2311 IND
Jul 2018
Innovation partnership with 908 Devices
Jan 2019
Mabspace & HJB merged to establish Transcenta
Mar 2019
In-licensed Blosozumab (TST002) from Eli Lilly
Jun 2019
NMPA Clearance of JCT205 IND
Jan 2020
Transcenta completed series B+ US$ 100M
Apr 2020
NMPA and FDA Clearance of TST001 IND
Jul 2020
First Patient Dosed in Phase I Clinical Trial of TST001 in the US
Aug 2020
First Patient Dosed in Phase I Clinical Trial of TST001 in China
Dec 2020
Closes US$105 Million in Crossover Financing
Feb 2021
Achieved > 6 g/L PER Day Volumetric Productivity in Continuous Perfusion Platform
Apr 2021
First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX
Apr 2021
FDA Clearance of TST005 IND
July 2021
Promising Anti-tumor Responses Have Been Observed in the TST001 Trials
July 2021
NMPA Acceptance of TST002 IND
July 2021
First Patient Dosed in Global Phase I Clinical Trial of TST005 in thr US

Albert Zhu CPA

SVP Finance Business Operations

Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting. In addition, he also participated in a number of M&A consulting projects to assist domestic and foreign clients to carry out due diligence, design trading structure, to ensure smooth transactions, as well as to carry out the integration of the financial sector to improve the clients and the target companies’ financial system and processes. Albert has received his bachelor degree from Sun Yat-sen University and is a member of the CICPA and the ACCA.